Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Precision protein engineering generates superior molecules
3 product candidates in the clinic as a result of research innovations
Great people making excellence happen, every day!
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Webcast, CLICK HERE Download Presentation, CLICK HERE
https://www.biospace.com/article/sutro-maximizes-synergy-to-treat-cancer-and-preserve-quality-of-life/ By: Heather McKenzie Published: Jan. 12, 2021 Sutro Biopharma wants to use its antibody-drug conjugates (ADCs) as “laser-guided weapons” against cancer cells...